Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liver Cancer Drug Market To Triple By 2014; MNCs Will Take Lead

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Sales of hepatocellular carcinoma drugs in China will nearly triple from $53 million in 2009 to $144 million in 2014, a new research report from Decision Resources found

You may also be interested in...



China Likely To Delay Drug Price Cuts Until Next Year: Good News Or Bad?

SHANGHAI - The National Development and Reform Commission, China's leading economic regulatory body, is revising a drug price control plan that was issued in June for public feedback after receiving industry-led objections to some proposals

China's Health System Reforms Are Opening Gates To Creating Gigantic Pharmacy Chains, Says One Would-be Titan

BEIJING - The first phase of Beijing's healthcare reforms, centered on expanding medical facilities across the hinterland and extending insurance coverage to rural residents, is creating massive opportunities for drug retailers to form giant chain stores to march through and occupy the Chinese countryside, say the leaders of would-be giant BioPharm Asia

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel